BEIJING SUCCEEDER TECHNOLOGY INC.

The fourth important consensus document, spearheaded by the Thrombosis and Hemostasis Committee of the Chinese Association of Research Hospitals, has been released.

The "Expert Consensus on Clinical Monitoring of Heparin-like Drugs" was jointly developed by the Thrombosis and Hemostasis Committee of the Chinese Association of Research Hospitals and the Laboratory Science Branch of the Chinese Geriatrics Society. This document, jointly authored by multidisciplinary experts from across China, took two years to develop, following numerous discussions and revisions. The final draft was finally agreed upon and published in August 2025 in the Chinese Journal of Laboratory Medicine, Volume 48, Issue 8.

This consensus provides standardized guidance for laboratory monitoring of heparin-like drugs, offering more reliable laboratory support for the safe and effective implementation of clinical anticoagulant therapy. Ultimately, it will benefit a wide range of patients and make heparin anticoagulant therapy more standardized and precise.

ABSTRACT

Heparin-like drugs are commonly used anticoagulants for the prevention and treatment of thromboembolic diseases. Proper use and appropriate monitoring of these drugs are crucial to ensuring the safety and effectiveness of treatment. This expert consensus draws on relevant domestic and international literature, fully considering the current status and progress of heparin use. It convened a panel of experts in the antithrombotic field, including laboratory and clinical experts, to discuss the indications, dosage, and monitoring of heparin. In particular, it clarified the clinical application of laboratory indicators such as anti-Xa activity and formulated expert recommendations with the goal of promoting the safe and effective use of heparin and standardizing laboratory monitoring.This article is a reprint from: Thrombosis and Hemostasis (CSTH).

Beijing Succeeder Technology Inc. (stock code: 688338) has been deeply engaged in the field of coagulation diagnosis since its establishment in 2003, and is committed to becoming a leader in this field. Headquartered in Beijing, the company has a strong R&D, production and sales team, focusing on the innovation and application of thrombosis and hemostasis diagnostic technology.

With its outstanding technical strength, Succeeder has won 45 authorized patents, including 14 invention patents, 16 utility model patents and 15 design patents. The company also has 32 Class II medical device product registration certificates, 3 Class I filing certificates, and EU CE certification for 14 products, and has passed ISO 13485 quality management system certification to ensure the excellence and stability of product quality.

Succeeder is not only a key enterprise of the Beijing Biomedicine Industry Leapfrog Development Project (G20), but also successfully landed on the Science and Technology Innovation Board in 2020, achieving leapfrog development of the company. At present, the company has built a nationwide sales network covering hundreds of agents and offices. Its products are sold well in most parts of the country. It is also actively expanding overseas markets and continuously improving its international competitiveness.